Baidu
map

Sci Rep:肌肉浸润性膀胱癌中关键lncRNA的亚型特异性表达和生存预测

2020-12-16 AlexYang MedSci原创

膀胱癌的综合转录组表达分析揭示了具有不同分子和临床特征的独特lncRNA簇。

膀胱癌的综合转录组表达分析揭示了具有不同分子和临床特征的独特lncRNA簇。

最近,有研究人员评估了关键lncRNA对生存的影响及其在分子膀胱癌亚型之间的差异表达。研究人员在Nanostring nCounter平台上分析了来自无化疗肌肉浸润性膀胱癌(MIBC)患者的FFPE样本,并进行了绝对定量;建立了包括36个基因的panel进行分子亚型分类,包括基底型、腔隙型和浸润型MIBC。之后研究人员评估了14个关键lncRNA的分子亚型归属,以及它们在疾病特异性生存中的预测价值。研究人员在总共487名MIBC患者(MDA、TGCA和Chungbuk队列)上进行了芯片验证。研究发现,几个关键的lncRNA表现出独特的分子亚型归属:如MALAT1在基底亚型中表现出下调(p=0.009),TUG1和CBR3AS1在腔隙亚型中表现出上调(p≤0.001)。SNHG16、CBR3AS1和H19的高转录水平似乎预示着较短的疾病特异性生存。在MIBC组织中过量表达假定的致癌基因MALAT1和TUG1的患者表现出较长的生存期,表明了这两种lncRNAs具有肿瘤抑制作用。

MIBC分子亚型中lncRNA的差异表达情况

另外,他们的研究证明了Nanostring nCounter是一个有效的低丰度转录物(包括lncRNAs)的定量平台

原始出处:

Sebastien Rinaldetti, Thomas Stefan Worst, Eugen Rempel et al. Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer. Sci Rep. Nov 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1899443, encodeId=48b818994431a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jun 16 17:42:41 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005747, encodeId=87532005e470b, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Jan 26 13:42:41 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301942, encodeId=ab1a1301942c9, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Dec 18 12:42:41 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040000, encodeId=b941104000030, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 17 00:42:41 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908715, encodeId=e9a1908e1546, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Dec 16 22:05:11 CST 2020, time=2020-12-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1899443, encodeId=48b818994431a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jun 16 17:42:41 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005747, encodeId=87532005e470b, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Jan 26 13:42:41 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301942, encodeId=ab1a1301942c9, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Dec 18 12:42:41 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040000, encodeId=b941104000030, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 17 00:42:41 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908715, encodeId=e9a1908e1546, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Dec 16 22:05:11 CST 2020, time=2020-12-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1899443, encodeId=48b818994431a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jun 16 17:42:41 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005747, encodeId=87532005e470b, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Jan 26 13:42:41 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301942, encodeId=ab1a1301942c9, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Dec 18 12:42:41 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040000, encodeId=b941104000030, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 17 00:42:41 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908715, encodeId=e9a1908e1546, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Dec 16 22:05:11 CST 2020, time=2020-12-16, status=1, ipAttribution=)]
    2020-12-18 xzw113
  4. [GetPortalCommentsPageByObjectIdResponse(id=1899443, encodeId=48b818994431a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jun 16 17:42:41 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005747, encodeId=87532005e470b, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Jan 26 13:42:41 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301942, encodeId=ab1a1301942c9, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Dec 18 12:42:41 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040000, encodeId=b941104000030, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 17 00:42:41 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908715, encodeId=e9a1908e1546, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Dec 16 22:05:11 CST 2020, time=2020-12-16, status=1, ipAttribution=)]
    2020-12-17 留走人康

    膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1899443, encodeId=48b818994431a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Wed Jun 16 17:42:41 CST 2021, time=2021-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2005747, encodeId=87532005e470b, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Tue Jan 26 13:42:41 CST 2021, time=2021-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301942, encodeId=ab1a1301942c9, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Fri Dec 18 12:42:41 CST 2020, time=2020-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040000, encodeId=b941104000030, content=膀胱癌真怪,明明是免疫敏感性肿瘤,为什么PD-1治疗效果不好呢?难道靶点不对?将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Thu Dec 17 00:42:41 CST 2020, time=2020-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=908715, encodeId=e9a1908e1546, content=学习!, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f435296195, createdName=ms3000000449926787, createdTime=Wed Dec 16 22:05:11 CST 2020, time=2020-12-16, status=1, ipAttribution=)]
    2020-12-16 ms3000000449926787

    学习!

    0

相关资讯

Sci Rep:肌肉浸润性或转移性膀胱癌患者化疗的模式和临床结果

最近,有研究人员进行了一项回顾性研究,评估了肌肉浸润性或转移性膀胱癌(MIBC/mBC)化疗治疗患者的真实世界肿瘤学结果,并将结果与RCTs和其他队列的数据进行了比较。

Sci Rep:膀胱癌开放染色质区域分析阐释β-catenin变异和Wnt信号与膀胱癌神经元亚型的联系

膀胱尿道癌是最常见的膀胱癌,每年影响40多万人。在组织病理学上,它主要分为肌层浸润性膀胱癌(MIBC)和非肌层浸润性膀胱癌(NMIBC)。最近,主要由TCGA等联盟推动的研究揭示了MIBC和NMIBC

Sci Rep:UBC9协调炎症来影响膀胱癌的发展

SUMO修饰失调与致癌有关。UBC9是类泛素化中唯一的共轭酶,在维持稳态和抑制应激反应方面起着关键的作用。然而,UBC9在膀胱癌中的临床意义和功能仍不清楚。

Sci Rep:埃及血吸虫特异性microRNA作为血吸虫性膀胱癌预测和预后工具的作用

泌尿系膀胱癌是埃及常见的恶性肿瘤,因此需要可靠的方法进行筛查和早期检测。

Sci Rep:膀胱癌中作为预后因子的免疫相关基因鉴定

膀胱癌是全球最常见的癌症之一。免疫反应和免疫细胞浸润在肿瘤进展中起着关键的作用。在过去十年,免疫治疗在膀胱癌方面取得了突破性的成就。

Cell Death & Disease:DEPDC1B是膀胱癌发展的促进剂

膀胱癌是泌尿系统最常见的恶性肿瘤之一,并导致大量癌症相关的死亡。DEPDC1B是一种含DEP结构域的蛋白,已被发现与多种人类癌症相关。

Baidu
map
Baidu
map
Baidu
map